All In Biotech

Drug Trial Radar · NCT07586306

A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD)

A Clinical Study Evaluating Subretinal Injection of VGR-R01 in the Contralateral Eye of Participants With Bietti's Crystalline Dystrophy Who Had Received VGR-R01 Administration

Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jun 1, 2026

Primary completion

Jul 31, 2027

Study completion Jul 31, 2031

Sponsor

Sponsor type
Industry
First posted
May 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-centre, single- arm, non-randomized, open-label phase 1/2 clinical trial which enables dosing of the fellow eyes of patients who received VGR-R01 administration in previous studies.

Conditions

  • Bietti Crystalline Dystrophy

Interventions

  • VGR-R01Biological

    CYP4v2-coding gene delivered by AAV vector

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events and serious adverse eventsTime frame: Up to Year 5
  2. Number of participants with clinically significant change from baseline in vital signs, clinically laboratory abnormalities and ophthalmic examination findingsTime frame: Up to Year 5

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital

    Beijing, Beijing Municipality, China

  • Shanghai General Hospital (Shanghai First People's Hospital)

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.